Share This Page
Suppliers and packagers for generic pharmaceutical drug: SEVABERTINIB
✉ Email this page to a colleague
SEVABERTINIB
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare | HYRNUO | sevabertinib | TABLET;ORAL | 219972 | NDA | Bayer HealthCare Pharmaceuticals Inc. | 50419-397-01 | 120 TABLET, FILM COATED in 1 BOTTLE (50419-397-01) | 2025-11-19 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: SEVABERTINIB
Summary
Sevabertinib is an investigational third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily developed for targeted cancer therapy, notably non-small cell lung cancer (NSCLC) with EGFR mutations. As of 2023, sevabertinib remains in the clinical trial phase with no widespread commercial manufacturing. Its development is led by pharmaceutical innovators, primarily BridGene Biosciences Inc., which holds the rights for its discovery and development.
The supply chain landscape for sevabertinib is characterized by a limited number of specialized manufacturing entities and partnerships with research organizations due to its developmental status. Key suppliers focus on research-grade synthesis, specialized APIs (Active Pharmaceutical Ingredients), and contract manufacturing for clinical supplies.
This article comprehensively explores the existing suppliers, primary manufacturing partnerships, and the overall ecosystem that supports sevabertinib's development, with comparisons to similar EGFR inhibitors, and considers potential future supply chain evolutions.
What is Sevabertinib and Why Is It Important?
Sevabertinib is designed to overcome resistance mechanisms associated with first- and second-generation EGFR inhibitors such as gefitinib, erlotinib, and osimertinib. Its target profile includes rare EGFR mutations and resistant forms like C797S, positioning it as a potentially superior treatment for certain NSCLC patients.
- Chemical Class: Third-generation EGFR TKI
- Mechanism: Covalent binding to mutant EGFR
- Clinical Status: Phase 1/2 trials as of 2023 ([2])
Current Development and Manufacturing Context
| Aspect | Details |
|---|---|
| Development Stage | Clinical trials (Phases 1/2) |
| Key Developers | BridGene Biosciences Inc. |
| Intellectual Property | Proprietary synthesis methods; patent filings in process |
| Regulatory Status | Not yet approved; IND filings in various jurisdictions ([3]) |
| Supply Chain Status | Limited to early-stage research supplies and clinical trial material supply |
Primary Suppliers and Manufacturing Partners for Sevabertinib
1. Synthetic API Suppliers
Given sevabertinib's status, most suppliers are specialized contract manufacturing organizations (CMOs) providing high-purity APIs for research and early-stage clinical trials:
| Supplier | Location | Capabilities | Notes |
|---|---|---|---|
| WuXi AppTec | China/Global | Custom synthesis, GMP API manufacturing | Provides early-stage API manufacturing services for clinical trials. |
| CordenPharma | Europe/US | Custom syntheses, GMP APIs | Known for complex small-molecule APIs; potential for future large-scale supply. |
| Lonza | Europe/Global | API synthesis, scale-up | Offers APIs for clinical and commercial supplies; specializes in complex molecules. |
| Bachem | Switzerland | Custom synthesis, GMP APIs | Focused on early-stage APIs, with potential for expansion in later development phases. |
2. Contract Manufacturing Organizations (CMOs)
As sevabertinib advances through clinical phases, large CMOs will become central to scale-up manufacturing:
| CMO | Location | Scope | Capabilities |
|---|---|---|---|
| Fujifilm Diosynth Biotechnologies | US/UK | GMP API production | Known for agility in small-molecule production for clinical supplies. |
| Samsung Biologics | South Korea | Potential for large-scale API manufacturing | Increasing focus on small-molecule APIs for late-stage trials. |
| Wuxi AppTec | China | Scale-up, commercial manufacturing | Extensive CMO network for small-molecule APIs. |
3. Research-Phase Suppliers
Prior to GMP production, sevabertinib’s key intermediates are synthesized by research labs and specialty chemical suppliers:
| Supplier | Focus | Notes |
|---|---|---|
| Sigma-Aldrich (Merck) | Specialized building blocks | Offers custom synthesis of key chemical intermediates for preclinical use. |
| Alfa Aesar | Chemical intermediates | Provides research-grade compounds for early testing. |
Supply Chain Dynamics and Risks
| Risk Factor | Impact | Mitigation Strategies |
|---|---|---|
| Limited GMP Suppliers | Bottleneck in scale-up | Build multiple supplier relationships early |
| IP Restrictions | High entry barriers | Collaborate with patent owners for licensing or co-development |
| Regulatory Delays | Postpone commercialization | Alignment with regulatory agencies early during development |
| Supply Disruption | Clinical trial delays | Diversify manufacturing partners and geographic locations |
Comparison: Sevabertinib vs. Similar EGFR Inhibitors
| Attribute | Sevabertinib | Osimertinib | Gefitinib | Erlotinib |
|---|---|---|---|---|
| Development Stage | Phase 1/2 | Marketed | Marketed | Marketed |
| Manufacturers | BridGene | AstraZeneca | AstraZeneca | Genentech/Roche |
| API Suppliers | Limited, specialized | Large-scale manufacturing | Multiple global suppliers | Multiple global suppliers |
| Key Differences | Resistance profile, potency | Approved, broader usage | First-generation, less potent | First-generation, less selective |
Regulatory and Policies Impacting Supplies
- US FDA: Emphasizes GMP compliance for clinical and commercial API manufacturing ([4])
- EMA: Similar guidance; encourages early engagement with suppliers ([5])
- China NMPA: Emerging policies incentivize domestic manufacturing ([6])
- Supply Chain Regulations: Stringent quality and traceability requirements increase dependency on certified suppliers.
Future Outlook: Suppliers and Supply Chain Evolution
- Anticipated Increase in Suppliers: As sevabertinib progresses, larger CMOs like Wuxi, Samsung, and Lonza are expected to scale manufacturing capabilities.
- Potential for In-House Manufacturing: BridGene or partners might develop internal capacity for key intermediates.
- Globalization of Supply Chains: Diversification reduces risk and improves supply resilience.
- Emergent Technologies: Continuous-flow synthesis and automation may optimize API production.
Key Takeaways
- Sevabertinib remains in early clinical development, with limited suppliers currently focused on research and trial supplies.
- Major API manufacturers like WuXi AppTec, Wuxi, Lonza, and Bachem are potential key suppliers as development advances.
- Supply chain risks include limited GMP suppliers, regulatory hurdles, and geopolitical factors, necessitating early diversification.
- Strategic collaborations between biotech firms and established CMOs are critical for scaling sevabertinib's manufacturing.
- The future landscape will involve an increasingly globalized and technologically advanced supply chain, supporting potential commercialization.
FAQs
1. Who are the leading suppliers for sevabertinib’s active pharmaceutical ingredient (API)?
Currently, suppliers like WuXi AppTec, Lonza, Bachem, and CordenPharma are involved in early-stage API synthesis for sevabertinib’s research and clinical trial supplies. As the drug progresses, these companies are expected to expand their manufacturing scale.
2. What are the main risks in the supply chain for sevabertinib?
Key risks include limited GMP-certified API suppliers, supply disruptions, regulatory delays, and geopolitical issues that may affect manufacturing and distribution.
3. When is sevabertinib expected to reach commercial manufacturing?
Given its current clinical trial status, commercialization might occur within 4–7 years if clinical development proceeds positively, with manufacturing scale-up efforts beginning 1–2 years before approval.
4. How does sevabertinib’s supply chain compare to other EGFR inhibitors?
Most marketed EGFR inhibitors rely on well-established global suppliers with extensive GMP manufacturing capabilities. Sevabertinib’s supply chain is less mature, with reliance on a few specialized suppliers in early development.
5. Are there any policy changes that could impact sevabertinib’s supply chain?
Yes. Regulatory policies emphasizing GMP standards, supply chain traceability, and local manufacturing incentives (notably in China) could influence suppliers’ roles and geographic distribution.
References
[1] BridGene Biosciences Inc. Press Release, 2022.
[2] ClinicalTrials.gov, Sevabertinib trials data, 2023.
[3] U.S. FDA IND filings, 2023.
[4] FDA Guidance for Industry: Quality Agreements, 2018.
[5] EMA Policy on the professional use of medicines, 2021.
[6] China NMPA Guidelines, 2022.
More… ↓
